Ion channel-enhancing nanoparticles reprogram T cells in vivo for cancer immunotherapy

In head and neck squamous cell carcinoma (HNSCC), immunotherapy is frequently ineffective due to the impaired ability of tumor-infiltrating T cells to sustain calcium-dependent cytotoxic effector functions. Kv1.3 potassium channels in T cells are essential for maintaining membrane potential, which is necessary for Ca2+ influx; however, they are suppressed within the tumor microenvironment, and no pharmacologic Kv1.3 activators are currently available. To address this limitation, we developed lipid nanoparticles (LNPs) functionalized with anti-CD5 antibodies to specifically deliver mRNA encoding Kv1.3 (KCNA3) to T cells, thereby increasing channel expression and function. Treatment of human T cells with KCNA3-LNPs resulted in increased Kv1.3 channel protein levels and activity, leading to enhanced Ca 2+ influx and elevated secretion of effector cytokines (IL-2, IL-17, TNF-α, and IFN-γ) and cytotoxic molecules (Granzyme A, Perforin, Granulysin, and Fas ligand). In a human peripheral blood mononuclear cell-engrafted HNSCC humanized mouse model, peritumoral delivery of KCNA3-LNPs significantly reduced tumor burden and increased the infiltration of CD8⁺ Granzyme B⁺ cytotoxic T cells within the tumor, indicating improved antitumor immunity. Our study demonstrates that in vivo reprogramming of T cells through targeted Kv1.3 enhancement can overcome immunosuppressive barriers within the tumor microenvironment and enhance immune-mediated tumor clearance in vivo. This novel approach offers a scalable and cost-effective alternative to ex vivo T cell engineering and holds promise as a therapeutic strategy to improve immunotherapy outcomes in HNSCC and other solid tumors characterized by Kv1.3-dependent immune dysfunctions.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-18
DOI
https://doi.org/10.64898/2026.11.16.767140
Primary Topic
Immunotherapy and Immune Responses
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Ion channel-enhancing nanoparticles reprogram T cells in vivo for cancer immunotherapy

Abdulaziz O. Alshwimi, Laura Conforti, Benjamin H. Hinrichs, Marat V. Khodoun et al.
4 links
bioRxiv (Cold Spring Harbor Laboratory)
Immunotherapy and Immune Responses
preprint

Ion channel-enhancing nanoparticles reprogram T cells in vivo for cancer immunotherapy

Abdulaziz O. Alshwimi, Laura Conforti, Benjamin H. Hinrichs, Marat V. Khodoun, Hannah S. Newton, Ameet Ajit Chimote, Anjali Iyer, Shweta Swain
preprint en

Abstract

In head and neck squamous cell carcinoma (HNSCC), immunotherapy is frequently ineffective due to the impaired ability of tumor-infiltrating T cells to sustain calcium-dependent cytotoxic effector functions. Kv1.3 potassium channels in T cells are essential for maintaining membrane potential, which is necessary for Ca2+ influx; however, they are suppressed within the tumor microenvironment, and no pharmacologic Kv1.3 activators are currently available. To address this limitation, we developed lipid nanoparticles (LNPs) functionalized with anti-CD5 antibodies to specifically deliver mRNA encoding Kv1.3 (KCNA3) to T cells, thereby increasing channel expression and function. Treatment of human T cells with KCNA3-LNPs resulted in increased Kv1.3 channel protein levels and activity, leading to enhanced Ca 2+ influx and elevated secretion of effector cytokines (IL-2, IL-17, TNF-α, and IFN-γ) and cytotoxic molecules (Granzyme A, Perforin, Granulysin, and Fas ligand). In a human peripheral blood mononuclear cell-engrafted HNSCC humanized mouse model, peritumoral delivery of KCNA3-LNPs significantly reduced tumor burden and increased the infiltration of CD8⁺ Granzyme B⁺ cytotoxic T cells within the tumor, indicating improved antitumor immunity. Our study demonstrates that in vivo reprogramming of T cells through targeted Kv1.3 enhancement can overcome immunosuppressive barriers within the tumor microenvironment and enhance immune-mediated tumor clearance in vivo. This novel approach offers a scalable and cost-effective alternative to ex vivo T cell engineering and holds promise as a therapeutic strategy to improve immunotherapy outcomes in HNSCC and other solid tumors characterized by Kv1.3-dependent immune dysfunctions.

bioRxiv (Cold Spring Harbor Laboratory)
University of Cincinnati (US)
University of Cincinnati, National Institutes of Health, College of Medicine, University of Cincinnati
Good health and well-being
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon